| Genelux Corporation Reports First Quarter 2025 Financial Results and Provides General Business Updates |
WESTLAKE VILLAGE, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the first quarter of 2025 and provided general business updates. |
globenewswire.com |
2025-05-06 20:10:00 |
Czytaj oryginał (ang.) |
| Genelux Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update |
– Alignment reached with U.S. Food and Drug Administration on key elements of the approval pathway for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer – |
globenewswire.com |
2025-03-28 18:10:00 |
Czytaj oryginał (ang.) |
| Down -29.7% in 4 Weeks, Here's Why Genelux Corporation (GNLX) Looks Ripe for a Turnaround |
Genelux Corporation (GNLX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock. |
zacks.com |
2025-03-28 12:36:09 |
Czytaj oryginał (ang.) |
| Genelux Corporation Announces Pricing of $10.5 Million Underwritten Offering of Common Stock |
WESTLAKE VILLAGE, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (“Genelux”) (Nasdaq: GNLX), a late clinical-stage immuno-oncology company, today announced the pricing of an underwritten offering of 3,000,000 shares of its common stock at an offering price of $3.50 per share. The gross proceeds to Genelux from the offering are expected to be $10.5 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Genelux. |
globenewswire.com |
2025-03-25 10:31:00 |
Czytaj oryginał (ang.) |
| Genelux Corporation Announces New Chief Financial Officer |
WESTLAKE VILLAGE, Calif., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Matthew Pulisic has joined the company as its new Chief Financial Officer, effective January 30, 2025. |
globenewswire.com |
2025-02-03 08:45:00 |
Czytaj oryginał (ang.) |
| Genelux Corporation to Participate in a Fireside Chat with H.C. Wainwright |
WESTLAKE VILLAGE, Calif., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO and Chairman of the Board will participate in a virtual fireside chat with H.C. Wainwright & Co. on December 16, 2024. |
globenewswire.com |
2024-12-13 09:01:00 |
Czytaj oryginał (ang.) |
| Genelux Corporation to Participate in Fireside Chat at the Guggenheim Inaugural Healthcare Innovation Conference |
WESTLAKE VILLAGE, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO and Chairman of the Board, will discuss clinical-stage programs, recent announcements, and upcoming milestones in a fireside chat at the Guggenheim Inaugural Healthcare Innovation Conference, taking place November 11-13, 2024, in Boston, Massachusetts. |
globenewswire.com |
2024-11-06 18:01:00 |
Czytaj oryginał (ang.) |
| Genelux: 2nd Half Of 2025 PRROC Data Is Major Inflection Point |
Topline results from phase 3 OnPrime/GOG-3076 study using Olvi-Vec for the treatment of patients with platinum-resistant recurrent ovarian cancer, are expected in the 2nd half of 2025. Interim data from phase 2 U.S. trial using Olvi-Vec for the treatment of patients with non-small cell lung cancer is expected mid-2025. Interim results from phase 1b/2 China study, using Olvi-Vec for the treatment of patients with small-cell lung cancer, are expected 2nd half of 2024. |
seekingalpha.com |
2024-10-31 12:59:07 |
Czytaj oryginał (ang.) |
| Genelux Corporation Announces First Patient Dosed in Phase 2 Trial Evaluating Systemic Therapy with Olvi-Vec in Non-Small Cell Lung Cancer |
– VIRO-25 trial to assess efficacy & safety of olvimulogene nanivacirepvec (Olvi-Vec) & platinum-doublet + physician's choice of immune checkpoint inhibitor compared to docetaxel in recurrent non-small cell lung cancer – |
globenewswire.com |
2024-10-22 20:01:00 |
Czytaj oryginał (ang.) |
| Genelux Corporation to Participate in the 2024 Maxim Healthcare Virtual Summit |
WESTLAKE VILLAGE, Calif., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO and Chairman of the Board, will participate at the 2024 Maxim Healthcare Virtual Summit taking place October 15-17, 2024. |
globenewswire.com |
2024-10-09 20:15:00 |
Czytaj oryginał (ang.) |
| Genelux Corporation to Present at the H.C. Wainwright Global Investment Conference |
WESTLAKE VILLAGE, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, Chairman and CEO, will discuss clinical-stage programs, recent announcements, and upcoming milestones in a fireside chat at the H.C. Wainwright Global Healthcare Conference, taking place September 9-11, 2024, in New York City, New York. |
globenewswire.com |
2024-09-03 20:01:00 |
Czytaj oryginał (ang.) |
| Genelux Corporation Reports Second Quarter 2024 Financial Results and Provides General Business Updates |
WESTLAKE VILLAGE, Calif., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the second quarter of 2024 and provided general business updates. |
globenewswire.com |
2024-08-14 20:05:00 |
Czytaj oryginał (ang.) |
| Genelux Corporation to Participate in Fireside Chat at BTIG's Virtual Biotechnology Conference 2024 |
WESTLAKE VILLAGE, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO and Chairman, will discuss clinical-stage programs, recent announcements, and upcoming milestones in a fireside chat at BTIG's Virtual Biotechnology Conference 2024. |
globenewswire.com |
2024-07-30 11:00:00 |
Czytaj oryginał (ang.) |
| Genelux Corporation Announces Pricing of Approximately $27.5 Million Underwritten Offering of Common Stock and Accompanying Warrants |
WESTLAKE VILLAGE, Calif., May 24, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (Genelux) (Nasdaq: GNLX), a late clinical-stage immuno-oncology company, today announced the pricing of an underwritten offering of 6,875,000 shares of its common stock and accompanying warrants to purchase 6,875,000 shares of its common stock at a combined offering price of $4.00 per share and accompanying warrant, in each case before underwriting discounts and commissions. |
globenewswire.com |
2024-05-24 12:00:00 |
Czytaj oryginał (ang.) |
| Genelux Corporation Announces Proposed Public Offering of Common Stock and Warrants |
WESTLAKE VILLAGE, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (Genelux) (Nasdaq: GNLX), a late clinical-stage immuno-oncology company, today announced that it has commenced an underwritten public offering of its common stock and accompanying warrants. |
globenewswire.com |
2024-05-23 20:01:00 |
Czytaj oryginał (ang.) |
| Genelux Corporation Reports First Quarter 2024 Financial Results and Provides General Business Updates |
WESTLAKE VILLAGE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the first quarter of 2024 and provided general business updates. |
globenewswire.com |
2024-05-09 20:25:00 |
Czytaj oryginał (ang.) |
| Down -48.37% in 4 Weeks, Here's Why Genelux Corporation (GNLX) Looks Ripe for a Turnaround |
Genelux Corporation (GNLX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock. |
zacks.com |
2024-04-26 14:36:09 |
Czytaj oryginał (ang.) |
| Down -45.44% in 4 Weeks, Here's Why Genelux Corporation (GNLX) Looks Ripe for a Turnaround |
The heavy selling pressure might have exhausted for Genelux Corporation (GNLX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal. |
zacks.com |
2024-04-23 14:36:06 |
Czytaj oryginał (ang.) |
| After Plunging -26.21% in 4 Weeks, Here's Why the Trend Might Reverse for Genelux Corporation (GNLX) |
Genelux Corporation (GNLX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term. |
zacks.com |
2024-04-05 14:35:15 |
Czytaj oryginał (ang.) |
| All You Need to Know About Genelux Corporation (GNLX) Rating Upgrade to Buy |
Genelux Corporation (GNLX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
zacks.com |
2024-04-04 17:02:21 |
Czytaj oryginał (ang.) |
| Genelux Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update |
– Continued active enrollment of Olvi-Vec in our pivotal Phase 3 OnPrime/GOG-3076 trial in platinum resistant/refractory ovarian cancer with topline results anticipated in 2H 2025 – – Initiation of Phase 2 trial in non-small cell lung cancer (recurrent/platinum-ICI failure) with systemic administration of Olvi-Vec expected in 1H 2024 – – Ongoing Phase 1b/2 trial with systemic administration of Olvi-Vec in small cell lung cancer expected interim readout in 2H 2024 – – $23.2 million in cash, cash equivalents and short-term investments – WESTLAKE VILLAGE, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, reported fourth quarter and full year 2023 financial results and business updates. |
globenewswire.com |
2024-04-01 11:00:00 |
Czytaj oryginał (ang.) |
| Genelux Corporation Receives FDA Fast Track Designation for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer |
- Pivotal Phase 3 Study of Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer Initiated in September 2022 - - Phase 2 Trial of Olvi-Vec- Demonstrated Clinical Reversal of Platinum Resistance and Refractoriness and Met Primary Endpoint of Objective Response Rate with Durable Responses - WESTLAKE VILLAGE, Calif., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that the United States Food and Drug Administration (FDA) has granted Fast Track designation for the development program of Olvi-Vec (olvimulogene nanivacirepvec) for the treatment of patients with platinum resistant/refractory ovarian cancer. |
globenewswire.com |
2023-11-27 09:00:00 |
Czytaj oryginał (ang.) |
| Genelux Corporation Reports Third Quarter 2023 Financial Results and Provides General Business Updates |
- Expanded executive team as Lourie Zak appointed Chief Financial Officer - - Extended clinical focus on systemic administration in small cell lung cancer - - $29.9 million in cash and equivalents - WESTLAKE VILLAGE, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the third quarter of 2023 and provided general business updates. |
globenewswire.com |
2023-11-14 19:50:00 |
Czytaj oryginał (ang.) |
| Genelux Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
WESTLAKE VILLAGE, Calif., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that on September 11, 2023, the Company's Board of Directors (the “Board”) granted inducement awards consisting of non-qualified stock options to purchase 444,300 shares of common stock to seven new employees under the Company's 2023 Inducement Plan, including an option to purchase 150,000 shares of common stock to Lourie Zak, the Company's new Chief Financial Officer, an option to purchase 88,000 shares of common stock to Caroline Jewett, the Company's new Head of Quality, and an option to purchase 54,000 shares of common stock to Ralph Smalling, the Company's new Head of Regulatory. The Board approved the awards as an inducement material to such new employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4). |
globenewswire.com |
2023-09-14 11:00:00 |
Czytaj oryginał (ang.) |
| Genelux Corporation to Present at the H.C. Wainwright Global Investment Conference |
WESTLAKE VILLAGE, Calif., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, Chairman and CEO, will present a corporate overview with institutional investors during the H.C. Wainwright 25th Annual Global Investment Conference held the week of September 11t h, 2023. |
globenewswire.com |
2023-09-07 20:01:00 |
Czytaj oryginał (ang.) |